Case Report: Primary hepatic neuroendocrine tumor: two cases report with literature review

Yongsheng Tang, Xianyu Chen, Lu Xu, Zenan Yuan, Yang Yang, Chunhui Qiu, Hua LiFrontiers in Oncology 2023 · DOI

TL;DR

Primary hepatic neuroendocrine tumors (PHNETs) are rare "diagnostic chameleons" often mistaken for metastatic disease or other liver cancers. This paper details two successful cases where a multi-modal approach—combining advanced PET-CT imaging, immunohistochemistry, and Transarterial Embolization (TAE) with targeted drug therapy—achieved disease stability and high quality of life for patients with unresectable tumors.

What Problem Does This Paper Address?

The liver is a common site for metastatic neuroendocrine tumors (NETs) originating in the GI tract or lungs, but primary hepatic neuroendocrine tumors (PHNETs) are exceptionally rare, accounting for less than 1% of all NETs.

Because they lack specific clinical symptoms and often mimic hepatocellular carcinoma (HCC) or metastatic disease on standard CT/MRI scans, they are frequently misdiagnosed. Furthermore, because they are so rare, there is no "gold standard" treatment protocol, especially for patients who are not candidates for radical surgery due to multiple lesions or distant metastasis. The authors aim to standardize the diagnostic pipeline and evaluate the efficacy of non-surgical interventions.

Methods

The researchers employed a "triangulation" strategy for diagnosis and a personalized approach to treatment:

  • Advanced Imaging: Beyond standard CT/MRI, the authors used 18F-FDG PET-CT (to measure glucose metabolism) and Ga68-DOTATATE PET-CT (which targets somatostatin receptors specific to neuroendocrine cells).
  • Pathological Verification: Ultrasound-guided needle biopsies were analyzed using immunohistochemistry (IHC) for markers like Synaptophysin (Syn), Chromogranin A (CgA), and Ki-67 (a proliferation index).
  • Interventional Radiology: For treatment, they used Transarterial Embolization (TAE)—injecting embolic agents directly into the tumor's blood supply to "starve" it.
  • Systemic Therapy: TAE was paired with individualized drug regimens, including chemotherapy (capecitabine/temozolomide), targeted therapy (sunitinib/anlotinib), or endocrine therapy (octreotide).

Datasets

As a clinical case report and review, the "data" consists of:

  • Primary Cases: Two elderly female patients (aged 64 and 74) treated at the Third Affiliated Hospital of Sun Yat-sen University.
  • Literature Review: A meta-analysis of 43 cases across 31 publications reported over the last 15 years to identify demographic trends and survival outcomes.

Key Insights and Ideas

  • The "Primary" Challenge: The hardest part of diagnosing PHNET is proving the tumor didn't come from somewhere else. The authors emphasize that a negative "search" for a primary tumor in the lungs or GI tract is mandatory before confirming a PHNET diagnosis.
  • Imaging Synergy: While 18F-FDG PET-CT is great for high-grade, aggressive tumors, Ga68-DOTATATE PET-CT is more sensitive for well-differentiated NETs. Using both provides a comprehensive metabolic and receptor-based map of the disease.
  • Surgery isn't the only path: While anatomical liver resection is the preferred treatment (with a reported 78% 5-year survival rate), this paper demonstrates that for unresectable cases, TAE combined with modern targeted drugs can maintain "stable disease" with minimal side effects.
  • IHC is the "Gold Standard": Markers like CgA and Syn are highly sensitive (up to 90%+) for these tumors, making pathology indispensable for differentiating PHNET from other liver malignancies.

Key Results

  • Case 1 (Grade 3 NET): After undergoing TAE and a sequence of targeted therapies (sunitinib then anlotinib), the patient remained stable at a 13-month follow-up with a good quality of life.
  • Case 2 (Grade 2 NET): Treated with TAE and monthly octreotide injections, the tumor size decreased, and the patient remained stable at a 12-month follow-up.
  • Literature Review Findings:
    • Demographics: 65% of cases were female; the median age was middle-aged to elderly.
  • Location: 51% of tumors were in the right lobe.
  • Survival: Patients receiving a combination of TACE/TAE and systemic therapy showed promising survival times, with some cases in the literature exceeding 25–36 months even without surgery.

Limitations and Future Work

  • Sample Size: As a report of only two cases, the findings are illustrative rather than statistically definitive.
  • Follow-up Duration: While 12–13 months of stability is positive, longer-term data (5+ years) is needed to compare the efficacy of TAE+drug therapy against traditional surgery.
  • Standardization: The authors note that because PHNET is so rare, large-scale randomized controlled trials (RCTs) are nearly impossible, making multi-center registries essential for future progress.
  • Future Direction: Exploring the role of Peptide Receptor Radionuclide Therapy (PRRT)—a "search and destroy" radiation treatment—for PHNET cases that express high levels of somatostatin receptors.

Summary updated

Abstract

Our findings suggest that a combination of serological, radiological, and immunohistochemical examinations can aid in the diagnosis of PHNET. In addition, we determined that TAE combined with drug therapy could be an effective method for controlling PHNET progression. Regular postoperative follow-ups are important for monitoring the prognosis and tumor progression status of patients with PHNET.
BibTeX
@inproceedings{tang2023case,
  author = {Yongsheng Tang and Xianyu Chen and Lu Xu and Zenan Yuan and Yang Yang and Chunhui Qiu and Hua Li},
  title = {{Case Report: Primary hepatic neuroendocrine tumor: two cases report with literature review}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1225583},
}
Figure